Cyclerion Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cyclerion Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q2 2024.
  • Cyclerion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$1.32M, a 68.4% increase year-over-year.
  • Cyclerion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $3.01M.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$5.26M, a 88.1% increase from 2022.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$44.1M, a 14.7% increase from 2021.
  • Cyclerion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$51.6M, a 33.6% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $3.01M -$1.32M +$2.86M +68.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $149K -$1.54M +$5.41M +77.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-07
Q4 2023 -$5.26M -$1.69M +$5.52M +76.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$10.8M $7.57M +$18.1M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$28.8M -$4.18M +$9.21M +68.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$38.1M -$6.95M +$6.02M +46.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-07
Q4 2022 -$44.1M -$7.22M +$10M +58.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$54.1M -$10.5M +$794K +7.03% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$54.9M -$13.4M +$2.79M +17.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$57.7M -$13M -$6.02M -86.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$51.6M -$17.2M +$2.01M +10.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$53.7M -$11.3M +$7.52M +40% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$61.2M -$16.2M +$3.35M +17.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$64.5M -$6.95M +$13.3M +65.6% Jan 1, 2021 Mar 31, 2021 10-Q 2023-05-12
Q4 2020 -$77.8M -$19.2M +$6.83M +26.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 -$84.6M -$18.8M +$8.51M +31.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$93.1M -$19.5M +$12.7M +39.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$106M -$20.2M +$17.2M +45.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$123M -$26.1M +$4.85M +15.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$128M -$27.3M +$1.97M +6.72% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$130M -$32.3M -$2.47M -8.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$127M -$37.4M -$12.1M -47.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$115M -$30.9M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$29.3M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$29.8M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$25.3M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.